InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody (Iv0240)

Description of InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody (Iv0240)

Introduction

InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody (Iv0240) is a novel therapeutic agent that has gained significant attention in the field of cancer immunotherapy. This bispecific antibody has been designed to target two key immune checkpoint molecules, PD-1 and PD-L1, which play a critical role in regulating the immune response and promoting tumor growth. In this article, we will provide a scientific description of the structure, activity, and potential applications of Iv0240.

Structure of Iv0240

Iv0240 is a bispecific antibody that has been generated by fusing the variable regions of anti-PD-1 and anti-PD-L1 antibodies. This unique structure allows Iv0240 to simultaneously bind to both PD-1 and PD-L1, effectively blocking their interaction and disrupting the immunosuppressive signaling pathway. The constant regions of Iv0240 are derived from human IgG1, providing the antibody with a longer half-life and enhanced effector functions.

Mechanism of Action

The main mechanism of action of Iv0240 is through the blockade of the PD-1/PD-L1 pathway. PD-1 is a receptor expressed on the surface of T cells, while PD-L1 is a ligand expressed on tumor cells and other immune cells. When PD-1 binds to PD-L1, it inhibits the activity of T cells, allowing tumors to evade the immune response. Iv0240 disrupts this interaction, allowing T cells to become activated and attack tumor cells.

In addition to blocking the PD-1/PD-L1 pathway, Iv0240 also has the potential to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). This means that Iv0240 can recruit other immune cells, such as natural killer cells and macrophages, to directly attack tumor cells.

Therapeutic Target

The primary therapeutic target of Iv0240 is cancer, particularly solid tumors. PD-1 and PD-L1 are highly expressed in many types of cancer, allowing tumors to escape the immune response. By targeting both PD-1 and PD-L1, Iv0240 has the potential to be more effective than single-target therapies in treating a wide range of cancers.

In addition to cancer, Iv0240 may also have potential therapeutic applications in autoimmune diseases. PD-1/PD-L1 pathway is also involved in regulating the immune response in autoimmune diseases. By blocking this pathway, Iv0240 may help to reduce the excessive immune response seen in these conditions.

Research Use

Apart from its potential as a therapeutic agent, Iv0240 also has significant research use. It can be used as a tool to study the PD-1/PD-L1 pathway and its role in cancer and autoimmune diseases. Iv0240 can also be used to evaluate the efficacy of combination therapies with other immunotherapies or chemotherapy drugs.

In addition, Iv0240 can be used in preclinical studies to assess its safety and efficacy before moving on to clinical trials. Its unique bispecific structure and mechanism of action make it a valuable tool for researchers in the field of cancer immunotherapy.

Conclusion

InVivoMAb Anti-Mouse PD-1 & PD-L1 Bispecific Antibody (Iv0240) is a promising therapeutic agent with a unique structure and mechanism of action. By targeting both PD-1 and PD-L1, Iv0240 has the potential to overcome the limitations of single-target therapies and provide a more effective treatment for cancer and autoimmune diseases. Its use in research also holds great value in furthering our understanding of the PD-1/PD-L1 pathway and developing new immunotherapies.